Evidence map›Paper›PMID 41514673›Full record

ArticleCancers2026

Integrating In Vitro Analytics for Improved Antibody-Drug Conjugate Candidate Selection.

Virginia Del Solar, Ali Saleh, Annarita Di Tacchio, Lena Sokol Becciolini, Gyoung Dong Kang, Bianka Jackowska, Yan Hu, Chao Gong, Angel Zhang, Leigh Hostetler and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Virginia Del SolarOncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.ORCID 0000-0001-9405-674X
Ali SalehOncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.ORCID 0000-0001-7663-5975
Annarita Di TacchioOncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.ORCID 0009-0000-1592-6322
Lena Sokol BeccioliniOncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.
Gyoung Dong KangOncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.
Bianka JackowskaOncology Targeted Discovery-Drug Candidate, Chemistry, AstraZeneca, London E1 2AX, UK.ORCID 0000-0002-4416-8847
Yan HuOncology Targeted Discovery-Drug Candidate Bioscience Research and Discovery, Translational Pharmacokinetics/Pharmacodynamics, AstraZeneca, Waltham, MA 02451, USA.ORCID 0009-0000-3724-6854
Chao GongOncology Targeted Discovery-Drug Candidate Bioscience Research and Discovery, Integrated Bioanalysis, AstraZeneca, Gaithersburg, MD 20878, USA.ORCID 0009-0002-1740-8320
Angel ZhangOncology Targeted Discovery-Drug Candidate Bioscience Research and Discovery, AstraZeneca, Gaithersburg, MD 20878, USA.
Leigh HostetlerOncology Targeted Discovery-Drug Candidate Bioscience Research and Discovery, AstraZeneca, Gaithersburg, MD 20878, USA.
Maximilliam LeeOncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.ORCID 0000-0003-2353-1085
Akbar H KhanOncology Targeted Discovery-Drug Candidate, Chemistry, AstraZeneca, Waltham, MA 02451, USA.
Abhisek MitraOncology Targeted Discovery-Drug Candidate Bioscience Research and Discovery, AstraZeneca, Gaithersburg, MD 20878, USA.
Mahammad AhmedOncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.ORCID 0000-0002-5627-8648
David TickleOncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.
Balakumar VijayakrishnanOncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.ORCID 0000-0002-0329-8565

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe development of antibody-drug conjugates (ADCs) presents significant scientific and operational challenges, from optimising conjugation chemistry and linker stability to establishing robust analytical controls. Advanced analytical methods, particularly the combination of plasma stability assays with enzymatic studies, are essential for early screening and characterisation of ADC candidates. Integrating these in vitro assays with powerful data analysis software accelerates structure-activity relationship assessments and the identification of stable compounds in plasma.

methodsThis article examines how combined analytical and computational approaches enhance candidate selection by offering valuable insights into the metabolic fate and stability risks of ADCs.

resultsOur research shows correlation between in vitro stability profiles and in vivo pharmacokinetic (PK) data, demonstrating the predictive power of early-stage analytical studies. Implementation of software-driven visualisation and analysis enables faster, data-informed decision making, streamlining the triage process to prioritise candidates with optimal PK and pharmacodynamics (PD) characteristics.

conclusionsThese findings highlight the critical need for integrated in vitro analytics and computational tools in efficient ADC development, supporting the selection of candidates with the greatest potential for clinical success and facilitating a more effective and accelerated path from discovery to clinical application.

Indexed as

ADC serum stabilityAntibody–drug conjugatescomputational integrationenzymatic assay

Identifiers

PMID41514673
PMCPMC12784668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.